"I am a better investor because I am a businessman, and a better businessman because I am an investor."..Warren Buffet.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And that net income is verifiable not like some OTC companies who hint at profit, this one has the financials to back it up.
ITEM 4: Management’s Discussion and Analysis or Plan of Operation:
The management is pleased with the current financial position of the company. Revenues
increased 231% compared to the corresponding period in 2010 and was 96% of the full year’s
revenue for the year ended June 30, 2011. Net income increased an impressive 298% with net
income at $ 2,529,725 for the period ended December 31, 2011 as compared to net income of
$848,983 for period ending December 31, 2010. The company also has a healthy cash position
with cash balance of $ 735,762 as at December 31, 2011. This is despite the fact that the
company added new equipment worth $ 2,122,535 during this period. This addition was made
entirely from internal accruals and it is the commitment of the management that all future
additions to the asset base would be from internal accruals only without any further dilution or
debt increases. There are no plans for dilution over the next 18 months.
The company’s order position is also healthy and management envisages total revenues
about 10% higher than previously projected in August, 2011. This is mainly due to the fact
that the Indian pharmaceutical industry is currently focusing on exports to the USA and a lot of
companies are looking to get their products approved by the FDA for US sales. All these are
potential clients and our Company has an advantage that due to the facilities being based in
India, we are able to deliver quick feedback to our clients and there is a degree of comfort
resulting in order generation.
In the current period, with the additions to equipment, now the company can take on an added
variety of jobs especially in the area of drug testing. Though there no commitments outstanding
for purchase of assets, the management plans to add more testing and other equipment in the
current year, with all expenditures being met from internal accruals only.
These additions to equipment have resulted in gross margins increasing to 32.55% from 31.46% in the
corresponding period of 2010. Though, operating margins increased by 0.53%, net income
increased by a phenomenal 298% over December 31, 2010.
Check out the latest IIS and Quarterly Update!! Link is below...
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=73674
GATA Year End 2011 Interim Financials...talk about getting numbers out fast...
http://www.groupeathena.com/FinancialsDec2011.pdf
GATA Security Details
Share Structure
Market Value1
$21,682,974
a/o Mar 02, 2012
Shares Outstanding
47,136,900
a/o Dec 31, 2011
Float
2,171,600
a/o Dec 31, 2011
Authorized Shares
100,000,000
a/o Dec 31, 2011
Looks like someone took a little off the table at $.54...talk about jumping the gun!!
GATA CERTIFICATION OF YEAR END RESULTS
I, D. Purohit, Chairman of the Board and President of Groupe Athena Inc., hereby certify that the financial
statements filed herewith and the attached notes, fairly present, in all material respects, the financial
position as of September 30, 2011, results of operations and cash flows for the period ending September 30,
2011, in conformity with accounting principles generally accepted in the United States, are consistently
applied.
Dated this 7th day of October, 2011
________-sd-______________
D. Purohit
CEO
http://www.groupeathena.com/FinancialsSept2011.pdf
I would bet that GATA is gonna stay in the top boards all day.
Those Quarterly YoY numbers are sexy.
Qtrly Revenue Growth (yoy): 128.70%
Gross Profit (ttm): N/A
EBITDA (ttm)6: 5.81M
Net Income Avl to Common (ttm): 3.79M
Diluted EPS (ttm): 0.08
Qtrly Earnings Growth (yoy): 182.90%
LOL...POW...right in the ticker indeed. Tons of information on this coming to market....
Share capital
On July 1, 2009 the company announced a forward split of 20 shares for every share held. This increased
the number of shares outstanding from 2,356.845 shares to 47,136,900 shares outstanding.
The management is pleased to announce that the company has complied with all the requirements of the
various regulatory agencies and the shares of the company were listed on pinksheets.com in April, 2010.
The ticker symbol of the company is “GATA”. On April 4, 2011 the company got eligibility from the
Depository Trust Company to allow electronic quotes and trading
I am sure that the DD has just begun for the traders in the room let alone the investors in the room. I like what I am seeing so far in a big way. GATA does not act like a Pink, one reason I am digging deep.
NOTE A - ORGANIZATION AND NATURE OF ACTIVITIES
Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1, 2008. Groupe Athena
Inc. (the “Company”) is a research and testing organization and helps various pharmaceutical companies in
India to get regulatory approvals and facilitate exports of pharmaceuticals to the United States.
The company has a research and marketing facility in India, employing 15 consultants and marketing
personnel. The company is working towards aggressively expanding it’s presence in the Indian
pharmaceutical industry and has various contracts on hand currently.
The Company is currently engaged in and devotes considerable time to financial planning, recruiting and
training sales personnel and establishing a market presence for its services. Though revenues are increasing
at a brisk pace, the management believes that a significant market presence and sales account base has yet
to be achieved.
The board of directors has the authority, without action by the Company's stockholders, to provide for the
issuance of preferred stock in one or more classes or series and to designate the rights, preferences and
privileges of each class or series, which may be greater than the rights of the common stock.
GATA...2011 Annual Report...link is here.
http://www.groupeathena.com/FinancialsSept2011.pdf
Well the European process to get things to market is most assuredly smoother than ours here in the US...no question about that.
GATA...Group Athena's commitment to Quality
Embarking on the journey to FDA approval can be frustrating and disappointing when the task is left in the wrong hands. Groupe Athena has a commitment toward each of our clients to provide the highest quality services and the most positive outcomes at the least expense to our clients. With unmatched knowledge of the FDA approval process, as well as experience and knowledge of the cultures in which we conduct our business, our consultants are ready to serve you.
Our services offer an initial consultation to enable us to plan and strategize with goals specific to your product or company’s needs. We deliver comprehensive consults throughout the inspection process including mock FDA inspections and mock product recalls to identify and solve breaches in compliance through assessment and modification. With the right knowledge about supplier audits, document preparation and filing processes, we are able to meet all regulations and requirements. We also provide guidelines to ensure quality throughout development.
Whether you are seeking FDA approval for biotechnical products, pharmaceuticals [OTC, prescription or generics], diagnostics, or medical equipment and devices, we have the quality resources to know what is needed during each step of the process to guide you through it and to qualify. Our past and existing clients know their needs are met by professionals, who put client satisfaction as their number one priority.
Groupe Athena takes the processes and strategies to obtain FDA approval seriously on behalf of our clients, and we are proud when subsequent approvals lead to medical breakthroughs and economic prosperity on all sides of the world
Hey that is great news. I am also getting tons of Twitter and FB chatter.
GEM, I had a friend go to Europe for back surgery so he could get an artificial disc in his back that has been 7 years waiting for FDA approval. He was there, back and recovered in two weeks. Talk about red tape...
Case Study 3:
An acquisition of a generic pharmaceutical company by a rival resulted in an order that required the divestiture of 3 products to a third party acquirer.
The responsibility of Groupe Athena was to act as the overseer for the divestiture to review: (1) the transfer of product, technology and marketing information, (2) the implementation of the technology by the acquiring company and (3) the subsequent verification that the client did not have access to the Confidential Business Information.
Case Study 2:
The Issue
A major specialty pharmaceutical and medical products manufacturer identified a need to improve inconsistent handling of service and complaint issues related to their marketed products. From both regulatory and business liability perspectives, it is critically important to pharmaceutical and medical device companies that they have robust and compliant drug safety monitoring processes. The company sought help from Groupe Athena to standardize and optimize their service and complaint handling process, while building an operating model and functional organizational structure to support their future growth objectives.
Our Approach
Groupe Athena provided consulting experience to augment the company’s internal Global Complaint Management team in the area of program support.
The Outcome
Groupe Athena formed an internal team at the client who was responsible for developing, maintaining, and integrating the program and working group plans, reporting progress to key decision makers, identifying and requesting additional resource requirements, and providing first-line quality assurance for program activities and deliverables.
Groupe Athena supported the team by developing and maintaining project plans, preparing agendas and updates, developing reference materials, facilitating and coordinating working sessions, documenting working group meeting progress and work products, assuring timely issue resolution, and assisting with the preparation of deliverables.
Check out these Case Studies. Unreal outcomes!!
Case Study 2:
The Issue
A major specialty pharmaceutical and medical products manufacturer identified a need to improve inconsistent handling of service and complaint issues related to their marketed products. From both regulatory and business liability perspectives, it is critically important to pharmaceutical and medical device companies that they have robust and compliant drug safety monitoring processes. The company sought help from Groupe Athena to standardize and optimize their service and complaint handling process, while building an operating model and functional organizational structure to support their future growth objectives.
Our Approach
Groupe Athena provided consulting experience to augment the company’s internal Global Complaint Management team in the area of program support.
The Outcome
Groupe Athena formed an internal team at the client who was responsible for developing, maintaining, and integrating the program and working group plans, reporting progress to key decision makers, identifying and requesting additional resource requirements, and providing first-line quality assurance for program activities and deliverables.
Groupe Athena supported the team by developing and maintaining project plans, preparing agendas and updates, developing reference materials, facilitating and coordinating working sessions, documenting working group meeting progress and work products, assuring timely issue resolution, and assisting with the preparation of deliverables.
Group Athena Case Studies Case Study 1:
A medical device manufacturer had a failing QC testing group though group facilities in Europe had a higher rate of productivity and much higher rate of efficiency in terms of fewer laboratory investigations and samples analyzed.
The project was to analyze the situation and produce a new laboratory solution to establish at least parity with the European laboratory.
The Process:
Both laboratories were assessed using PERT/CPM tools and the results were process mapped to discover the differences between the laboratories. Following this process the analytical laboratories were reviewed for similarities and an optimum process was developed for the process going forward.
With the optimum process in place a gap analysis was developed and a forward implementation plan was crafted. Part of the solution was a total redesign of the analytical laboratory as well as an upgrade of the operating practices.
Outcome:
The result of the project was a vastly improved operating situation with reduced laboratory investigations and an improved level of productivity and operating efficiency.
GATA Corporate Philosophy
With 12 consultants in offices in America and India, Groupe Athena is able to offer the highest quality assistance to Indian and South East Asian pharmaceutical and medical companies seeking FDA approval for their products to export to the USA. Education among our expert consultants include 3 PhDs, 9 Pharmacists, 2 MBAs and an attorney to provide a good knowledge of FDA rules and regulations, pharmaceutical knowledge and the corner stones to secure FDA approval for our clients.
With all Indian founders, Groupe Athena also has a reputation for being the first choice for FDA regulatory consultancy in the region for their ability to understand the obstacles and complications for Indian and South East Asian companies, as well as the requirements that would be expected by the Food and Drug Administration in America. We understand the values and the language and our experience and education on the subject matter, together with an absolute focus on client satisfaction and support has made us a leader in the field of FDA Consultancy.
Groupe Athena’s resources also includes a laboratory facility located in India to assist with testing and clinical trials for our clients.
We continuously strive to provide the most advanced consultancy services to aid medical and pharmaceutical companies in reaching their objectives. From concept to approval, our professional consultants will guide each client through development, regulatory compliance, and ultimately passing FDA inspection and obtaining FDA approval.
With a proven track record reflecting our results, we are a highly flexible company positioned to lead you through the FDA approval process, finding solutions to obstacles and consistently producing client satisfaction grounded on positive outcomes. The company is streamlined to bring the best knowledge to benefit our clients as a team of professionals, dedicated to each project from start to finish. Combined with understanding of the entire FDA approval process, the American, Indian, and South East Asian mindsets and the right education and experience to be considered experts, Groupe Athena is the only FDA Consultancy to employ to navigate the FDA compliance journ
Indeed. IMHO this is undervalued and not long for the sub $.50 range.
Our US FDA can be a quagmire of bureaucratic red tape just to get a fast track drug to market. This is why so many Americans go overseas for treatment of all types of diseases. GATA has the goods to make this stop.
If GATA's management team can produce and audit of their financials it will only entice more investors into the mix.
That is exactly what I want to know. Look at the share structure here and tell me how this is under $.50 let alone a buck...
GATA Security Details
Share Structure
Market Value
$21,682,974
a/o Mar 02, 2012
Shares Outstanding
47,136,900
a/o Dec 31, 2011
Float
2,171,600
a/o Dec 31, 2011
Authorized Shares
100,000,000
a/o Dec 31, 2011
Shareholders
Shareholders of Record
39
a/o Dec 31, 2011
I would bet the markets will want to see the final financials from the company. The interim numbers are solid, but QoQ and YoY are what funds need to jump in.
It does look like GATA will have record year end profits of over 40M USD.
One last time GATA news today!! Groupe Athena, Inc. Clarifies Previous Guidance, Addresses U.S. Drug Shortage
Groupe Athena (PC) (USOTC:GATA)
Today : Saturday 3 March 2012
Groupe Athena, Inc. (Pink sheets GATA.PK)
The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates. While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material. These forecasts are subject to risks identified under "Safe Harbor Statement" below.
Groupe Athena, Inc. (Pink sheets GATA.PK) has previously announced they have approximately $60 million in customer orders that they are processing and they expect to be able to convert at least two thirds or approximately $40 million into revenue for the current fiscal year. The company is extremely pleased to issue this guidance update and announce that due to several factors including additional order flow and the recent equipment acquisitions, revenue should increase at least 10% or a minimum of $4 million. Earnings are also expected to increase similarly.
The company also announced they are in talks with several regional drug manufacturers as part of an effort to help alleviate the recently announced severe, potentially life threatening shortage of vital cancer drugs in the United States including methatrexate, one of the most widely used. The company expects developments in the near term and has committed to make every effort to "fast track" any trials or regulatory filings necessary.
The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.
About Groupe Athena, Inc.
Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.
The company has a research and marketing facility in India that currently employs 16 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com.
For more information contact:Paul CornellCorporate Shareholder Relations, Inc.pcornell@totalpublicrelations.com
GATA - Daily Candlesticks
I woulda been stoked if GATA did 3M a year in sales...it is projecting a 40M plus year end PROFIT!! LOL, this is a Pink like pigs fly IMHO...
GATA interim financials from their company website. Look at the numbers here. Unreal.
http://www.groupeathena.com/FinancialsDec2011.pdf
Well Gem, in a nutshell I am ready for liftoff. If GATA breaks the half dollar mark it could get noisy around here.
What GATA offer from their webiste!! Services Offered:
http://www.groupeathena.com/
Analytical QC
QA Functions
Readiness for Inspections
Compliance
Validation
Clinical Trial Management
Regulatory/Legal
Preparation of Regulatory Filings (IND's/PMA's/NDA's/ANDA's/510Ks etc)
Compliance Assessments (GLP, GMP, GXP)
Risk Assessments
Mock FDA Audits
Medical Device Support
CMC Support
GMP Training
Facility Layout Consulting
Utilities, Process, IT, Computer, and Cleaning Validation
Training
More GATA DD...Business Summary http://www.groupeathena.com/
Groupe Athena, Inc., a research and testing organization, provides technical and regulatory consulting services for biotechnical products, pharmaceuticals, diagnostics, medical equipment, and devices. The company helps various pharmaceutical companies in India and southeast Asia to get regulatory approvals and facilitate exports of pharmaceuticals to the United States. Its services include analytical QC, QA functions, readiness for inspections, compliance, validation, clinical trial management, regulatory/legal, preparation of regulatory filings, compliance assessments, risk assessments, mock FDA audits, medical device support, CMC support, GMP training, facility layout consulting, and training, as well as utilities, process, IT, computer, and cleaning validation. The company was founded in 2008 and is based in Mumbai, India
GATA guidance from the news today! Groupe Athena, Inc. (Pink sheets GATA.PK)
The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates. While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material. These forecasts are subject to risks identified under "Safe Harbor Statement" below.
Groupe Athena, Inc. (Pink sheets GATA.PK) has previously announced they have approximately $60 million in customer orders that they are processing and they expect to be able to convert at least two thirds or approximately $40 million into revenue for the current fiscal year. The company is extremely pleased to issue this guidance update and announce that due to several factors including additional order flow and the recent equipment acquisitions, revenue should increase at least 10% or a minimum of $4 million. Earnings are also expected to increase similarly.
GATA!! About Groupe Athena, Inc.
Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.
The company has a research and marketing facility in India that currently employs 16 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com.
I know blades. 40M is stupid big for an OTC that has current status like GATA does. Looking like I am following some seriously smart money into this one. I will add more GATA come Monday.
I think you will enjoy the GATA DD Gem. Lots going on with this revenue projection. IMHO this will hit some scans this weekend and then it is off to the races. Let me know what your charting work comes up with. TIA
GATA NEWS TODAY!!
Groupe Athena, Inc. Clarifies Previous Guidance, Addresses U.S. Drug Shortage
Groupe Athena (PC) (USOTC:GATA)
Today : Saturday 3 March 2012
Groupe Athena, Inc. (Pink sheets GATA.PK)
The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates. While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material. These forecasts are subject to risks identified under "Safe Harbor Statement" below.
Groupe Athena, Inc. (Pink sheets GATA.PK) has previously announced they have approximately $60 million in customer orders that they are processing and they expect to be able to convert at least two thirds or approximately $40 million into revenue for the current fiscal year. The company is extremely pleased to issue this guidance update and announce that due to several factors including additional order flow and the recent equipment acquisitions, revenue should increase at least 10% or a minimum of $4 million. Earnings are also expected to increase similarly.
The company also announced they are in talks with several regional drug manufacturers as part of an effort to help alleviate the recently announced severe, potentially life threatening shortage of vital cancer drugs in the United States including methatrexate, one of the most widely used. The company expects developments in the near term and has committed to make every effort to "fast track" any trials or regulatory filings necessary.
The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.
About Groupe Athena, Inc.
Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.
The company has a research and marketing facility in India that currently employs 16 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com.
For more information contact:Paul CornellCorporate Shareholder Relations, Inc.pcornell@totalpublicrelations.com
GATA - Daily Candlesticks